Pathophysiology of depression and innovative treatments: Remodeling glutamatergic synaptic connections

Dialogues in Clinical Neuroscience

Volumn 16, Issue 1, 2014, Pages 11-27

  Duman, Ronald S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BDNF; Glutamate; Ketamine; MTORC1; Prefrontal cortex; Rapamycin; Scopolamine; Stress; Synaptogenesis

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 2 AMINO 3 (3,4 DICHLOROBENZYLOXY) 6 FLUOROBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; 4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; AMPA RECEPTOR; AMPA RECEPTOR AGONIST; ANTIDEPRESSANT AGENT; AZD 6765; BRAIN DERIVED NEUROTROPHIC FACTOR; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; KETAMINE; MAMMALIAN TARGET OF RAPAMYCIN; MEMANTINE; METABOTROPIC RECEPTOR AGONIST; MUSCARINIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SCOPOLAMINE; TETRAPEPTIDE; UNCLASSIFIED DRUG; GLUTAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ARTICLE; BRAIN REGION; CELL PROLIFERATION; CHRONIC STRESS; CLINICAL TRIAL (TOPIC); DEPRESSION; GLIA CELL; HIPPOCAMPUS; HUMAN; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PROTEIN EXPRESSION; SYNAPTIC TRANSMISSION; SYNAPTOGENESIS; ANIMAL; BRAIN; METABOLISM; PHYSIOLOGY;

ANIMALS; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; DEPRESSION; GLUTAMINE; HUMANS; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPTIC TRANSMISSION;

EID: 84898867072     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (105)

1. Kessler R, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:617-627.
2. Trivedi M, Rush AJ, Wisniewski SR, et al STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
3. Duman R, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59:1116-1127.
4. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008;455:894-902.
5. Savitz J, Drevets WC. Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide. Neurosci Biobehav Rev. 2009;33:699-771.
6. Berman R, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351-354.
7. Zarate CA Jr, Singh JB, Quiroz JA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry. 2006;163:153-155.
8. Furey M, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry. 2006;63:1121-1129.
9. Furey M, Khanna A, Hoffman EM, Drevets WC. Scopolamine produces larger antidepressant and antianxiety effects in women than in men. Neuropsychopharmacology. 2010;35:2479-2488.
10. Mayberg H. Targeted electrode-based modulation of neural circuits for depression. J Clin Invest. 2009;119:717-725.
11. Drevets W, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression. Brain Struct Funct. 2008;213:93-118.
12. MacQueen G, Frodl T. The hippocampus in major depression: evidence for the convergence of the bench and bedside in psychiatric research? Mol Psychiatry. 2011;16:252-264.
13. Banasr M, Valentine GW, Li XY, Gourley S, Taylor J, Duman RS. Chronic stress decreases cell proliferation in adult cerebral cortex of rat: Reversal by antidepressant treatment. Biol Psychiatry. 2007;62:496-504.
14. Rajkowska G, Miguel-Hidalgo JJ, Wei J, et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry. 1999;45:1085-1098.
15. Rajkowska G, Miguel-Hidalgo JJ. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets. 2007;6:219-233.
16. Kang H, Voleti B, Hajszan T, et al. Decreased expression of synapserelated genes and loss of synapses in major depressive disorder. Nat Med. 2012;18:1413-1417.
17. McEwen B. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev. 2007;87:873-904.
18. Shansky R, Morrison JH. Stress-induced dendritic remodeling in the medial prefrontal cortex: effects of circuit, hormones and rest. Brain Res. 2009;1293:108-113.
19. Liu RJ, Aghajanian GK. Stress blunts serotonin- and hypocretin-evoked EPSCs in prefrontal cortex: role of corticosterone-mediated apical dendritic atrophy. Proc Natl Acad Sci U S A. 2008;105:359-364.
20. McEwen B. The ever-changing brain: cellular and molecular mechanisms for the effects of stressful experiences. Dev Neurobiol. 2012;72:878-890.
21. Roozendaal B, McEwen BS, Chattarji S. Stress, memory and the amygdala. Nat Rev Neurosci. 2009;10:423-433.
22. Sahay A, Hen R. Hippocampal neurogenesis and depression. Novartis Found Symp. 2008;289:152-160.
23. Boldrini M, Underwood MD, Hen R, et al. Antidepressants increase neural progenitor cells in the human hippocampus. Neuropsychopharmacology. 2009;34:2376-2389.
24. Banasr M, Dwyer JM, Duman RS. Cell atrophy and loss in depression: reversal by antidepressant treatment. Curr Opin Cell Biol. 2012;23:730-737.
25. Rajkowska G, O'Dwyer G, Teleki Z, Stockmeier CA, Miguel-Hidalgo JJ. GABAergic neurons immunoreactive for calcium binding proteins are reduced in the prefrontal cortex in major depression. Neuropsychopharmacology. 2007;32:471-482.
26. Duman R, Voleti B. Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci. 2012;35:47-56.
27. Schmidt H, Shelton RC, Duman RS. Functional markers of depression: diagnosis, treatment and pathophysiology. Neuropsychopharmacology. 2011;36:2375-2394.
28. Yu H, Wang DD, Wang Y, Liu T, Lee FS, Chen ZY. Variant brain-derived neurotrophic factor Val66Met polymorphism alters vulnerability to stress and response to antidepressants. J Neurosci. 2012;32:4092-4101.
29. Krishnan V, Han MH, Mazei-Robison M, et al. AKT signaling within the ventral tegmental area regulates cellular and behavioral responses to stressful stimuli. Biol Psychiatry. 2008;64:691-700.
30. Taliaz D, Stall N, Dar DE, Zangen A. Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviors associated with depression and reduces neurogenesis. Mol Psychiatry. 2010;15:80-92.
31. Chen Z-Y, Jing D, Bath KG, et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science. 2006;314:140-143.
32. Magariños A, Li CJ, Gal Toth J, et al. Effect of brain-derived neurotrophic factor haploinsufficiency on stress-induced remodeling of hippocampal neurons. Hippocampus. 2011;21:253-264.
33. Chen H, Pandey GN, Dwivedi Y. Hippocampal cell proliferation regulation by repeated stress and antidepressants. Neuroreport. 2006;17:863-867.
34. Liu R, Lee FS, Li XY, Bambico F, Duman RS, Aghajanian GK. Brain-derived neurotrophic factor val66met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry. 2012;71:996-1005.
35. Chiaruttini C, Vicario A, Li Z, et al. Dendritic trafficking of BDNF mRNA is mediated by translin and blocked by the G196A (Val66Met) mutation. Proc Natl Acad Sci U S A. 2009;106:16481-16486.
36. Gatt J, Nemeroff CB, Dobson-Stone C, et al. Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. Mol Psychiatry. 2009;14:681-695.
37. Sheline Y, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry. 2003;160:1516-1518.
38. Bessa J, Ferreira D, Melo I, et al. Hippocampal neurogenesis induced by antidepressant drugs: an epiphenomenon in their mood-improving actions. Mol Psychiatry. 2009;14:764-773.
39. Magarinos A, McEwen BS. Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: involvement of glucocorticoid secretion and excitatory amino acid receptors. Neurosci. 1995;69:89-98.
40. Karpova N, Pickenhagen A, Lindholm J, et al. Fear erasure in mice requires synergy between antidepressant drugs and extinction training. Science. 2011;334:1731-1734.
41. Maya Vetencourt J, Sale A, Viegi A, et al. The antidepressant fluoxetine restores plasticity in the adult visual cortex. Science. 2008;320:385-388.
42. Holtmaat A, Svoboda K. Experience-dependent structural synaptic plasticity in the mammalian brain. Nat Rev Neurosci. 2009;10:647-658.
43. Kessels H, Malinow R. Synaptic AMPA receptor plasticity and behavior. Neuron. 2009;61:340-350.
44. Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ. Ketamine for depression: where do we go from here? Biol Psychiatry. 2012;72:537-547.
45. Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67:793-802.
46. Larkin G, Beautrais AL. A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol. 2011;14:1127-1131.
47. Roberts E, Curran HV, Friston KJ, Morgan CJ. Abnormalities in white matter microstructure associated with chronic ketamine use. Neuropsychopharmacology. 2014;39:329-338.
48. Wang C, Zheng D, Xu J, Lam W, Yew DT. Brain damages in ketamine addicts as revealed by magnetic resonance imaging. Front Neuroanat. 2013;7:23.
49. Behrens M, Ali SS, Dao DN, et al. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science. 2007;318:1645-1647.
50. Behrens M, Sejnowski TJ. Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex? Neuropharmacology. 2009;57:193-200.
51. Li N, Lee BY, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329:959-964.
52. Li N, Liu R-J, Dwyer J, et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry. 2011;69:754-761.
53. Cornwell B, Salvadore G, Furey M, et al. Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol Psychiatry. 2012;72:55-61.
54. Yoshihara Y, De Roo M, Muller D. Dendritic spine formation and stabilization. Curr Opin Neurobiol. 2009;19:146-153.
55. Koike H, Lijima M, Chaki S. Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists. Neuropharmacology. 2011;61:1419-1423.
56. Autry A, Adachi M, Nosyreva E, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011;475:91-95.
57. Laje G, Lally N, Mathews D, et al. Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol Psychiatry. 2012;72:27-28.
58. Shirayama Y, Ishida H, Iwata M, Hazama G-i, Kawahara R, Duman R. Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin blockade produces antidepressant effects. J Neurochem. 2004;90:1258-1268.
59. Russo S, Nestler EJ. The brain reward circuitry in mood disorders. Nat Rec Neurosci. 2013;14:609-625.
60. Schmidt H, Duman RS. Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology. 2010;35:2378-2391.
61. Blier P. Exploiting N-methyl-d-aspartate channel blockade for a rapid antidepressant response in major depressive disorder. Biol Psychiatry. 2013;74:238-239.
62. Kapur S, Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptorsimplications for models of schizophrenia. Mol Psychiatry. 2002;7:837-844.
63. Coates K, Flood P. Ketamine and its preservative, benzethonium chloride, both inhibit human recombinant alpha7 and alpha4beta2 neuronal nicotinic acetylcholine receptors in Xenopus oocytes. Br J Pharmacol. 2001;134:871-879.
64. Sanacora G, Zarate CA, Krystal JH, Manji HK. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov. 2008;7:426-437.
65. Lima-Ojeda J, Vogt MA, Pfeiffer N, et al. Pharmacological blockade of GluN2B-containing NMDA receptors induces antidepressant-like effects lacking psychotomimetic action and neurotoxicity in the perinatal and adult rodent brain. Prog Neuropsychopharmacol Biol Psychiatry. 2013;45:28-33.
66. Preskorn S, Baker B, Omo K, Kolluri S, Menniti FS, Landen JW. A placebo-controlled trial of the NR2B subunit specific NMDA antagonist CP-101,606 plus paroxetine for treatment resistant depression (TRD). Paper presented at the American Psychological Association meeting; 2007.
67. Zarate CA Jr, Du J, Quiroz J, et al. Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutmatergic system. Ann N Y Acad Sci. 2003;1003:273-291.
68. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333-1341.
69. Zarate CJ, Mathews D, Ibrahim L, et al. A randomized trial of a lowtrapping nonselective N-methyl-d-aspartate channel blocker in major depression. Biol Psychiatry. 2013;74:257-264.
70. Sanacora G, Smith MA, Pathak S, et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry. 2013. Epub ahead of print.
71. Burgdorf J, Zhang XL, Nicholson KL, et al. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology. 2012;38:729-742.
72. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17:2912-2917.
73. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci. 2007;27:11496-11500.
74. Shigemoto R, Kinoshita A, Wada E, et al. Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J Neurosci. 1997;17:7503-7522.
75. Hascup E, Hascup KN, Stephens M, et al. Rapid microelectrode measurements and the origin and regulation of extracellular glutamate in rat prefrontal cortex. J Neurochem. 2010;115:1608-1620.
76. Bespalov A, van Gaalen MM, Sukhotina IA, et al. Behavioral characterization of the mGlu group II/III receptor antagonist, LY-341495, in animal models of anxiety and depression. Eur J Pharmacol. 2008;592:96-102.
77. Chaki S, Yoshikawa R, Hirota S, et al. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressantlike activity. Neuropharmacology. 2004;46:457-467.
78. Marek G. Metabotropic glutamate2/3 (mGlu2/3) receptors, schizophrenia and cognition. Eur J Pharmacol. 2010;639:81-90.
79. Dwyer JM, Lepack AE, Duman RS. mTOR activation is required for the antidepressant effects of mGluR2/3 blockade. Int J Neuropsychopharmacol. 2012;15:429-434.
80. Dwyer J, Lepack AE, Duman RS. mGluR2/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure. J Mol Psych. In press.
81. Maeng S, Zarate CA Jr, Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008;63:349-352.
82. Arai A, Kessler M, Rogers G, Lynch G. Effects of the potent ampakine CX614 on hippocampal and recombinant AMPA receptors: interactions with cyclothiazide and GYKI 52466. Mol Pharmacol. 2000;58:802-813.
83. Lauterborn J, Lynch G, Vanderklish P, Arai A, Gall CM. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J Neurosci. 2000;20:8-21.
84. Arai A, Kessler M. Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior. Curr Drug Targets. 2007;8:583-602.
85. Lynch A, Walsh C, Delaney A, Nolan Y, Campbell VA, Lynch MA. Lipopolysaccharide-induced increase in signalling in hippocampus is abrogated by IL-10-a role for IL-1b? J Neurochem. 2004;88:635-646.
86. Jourdi H, Hsu YT, Zhou M, Qin Q, Bi X, Baudry M. Positive AMPA receptor modulation rapidly stimulates BDNF release and increases dendritic mRNA translation. J Neurosci. 2009;29:8688-8697.
87. Bai F, Li X, Clay M, Lindsrom T, Skolnick P. Intra- and interstrain differences in models of "behavior despair". Pharmacol Biochem Behav. 2001;70:187-192.
88. Bai F, Bergeron M, Nelson DL. Chronic AMPA receptor potentiator (LY451646) treatment increases cell proliferation in adult rat hippocampus. Neuropharmacology. 2003;44:1013-1021.
89. Voleti B, Navarria A, Liu RJ, et al. Scopolamine rapidly increases mTORC1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol Psychiatry. 2013;74:742-749.
90. Beurel E, Song L, Jope RS. Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry. 2011;16:1068-1070.
91. Liu RJ, Fuchikami M, Dwyer JM, Lepack AE, Duman RS, Aghajanian GK. GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. Neuropsychopharmacology. 2013;38:2268-2277.
92. Drevets W, Furey ML. Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry. 2010;67:432-438.
93. Vecsey C, Peixoto L, Choi JH, et al. Genomic analysis of sleep deprivation reveals translational regulation in the hippocampus. Physiol Genomics. 2012;44:981-991.
94. Caruana D, Warburton EC, Bashir ZI. Induction of activity-dependent LTD requires muscarinic receptor activation in medial prefrontal cortex. J Neurosci. 2011;31:18464-18478.
95. Harsing L, Zigmond MJ. Postsynaptic integration of cholinergic and dopaminergic signals on medium-sized GABAergic projection neurons in the neostriatum. Brain Res Bull. 1998;45:607-613.
96. Hughes Z, Liu F, Marquis K, et al. Estrogen receptor neurobiology and its potential for translation into broad spectrum therapeutics for CNS disorders. Curr Mol Pharmacol. 2009;2:215-236.
97. Woolley C, McEwen BS. Estradiol regulates hippocampal dendritic spine density via an N-methyl-D-aspartate receptor-dependent mechanism. J Neurosci. 1994;14:7680-7687.
98. Dowlati Y, Herrmann, N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67:446-457.
99. Howren M, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71:171-186.
100. Schiepers O, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:201-217.
101. Iwata M, Ota KT, Duman RS. The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. Brain Behav Immun. 2013;31:105-114.
102. Krishnan V, Han M-H, Graham DL, et al. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell. 2007;131:391-404.
103. Raison C, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70:31-41.
104. Koo J, and Duman RS. IL-1B is an essential mediator of the anti-neurogenic and anhedonic effects of stress. Proc Natl Acad Sci U S A. 2008;105:751-756.
105. Paolicelli R, Bolasco G, Pagani F, et al. Synaptic pruning by microglia is necessary for normal brain development. Science. 2011;333:1456-1458.